PDCD1 and acute lymphoblastic leukemia: Taken together, our results indicate that PD-1 is central to mediating the in vivo escape of B-ALL cells from surveillance by NK cells, and that PD-1 targeting conferred clinical benefits by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL.